The measurement of minimal residual disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.
This programme issues stabilised whole blood with laboratories required to determine the level of minimal residual disease by flow cytometry, please note this programme is not suitable for the measurement of MRD by molecular methods.
Each send out includes two follow up samples of a known CLL case post treatment at different time points. Participants will be asked to quantify the level of residual disease in these samples
Two samples are issued per trial and this programme issues samples a minimum of 2 times per annum and a maximum of 4.
No activities in relation to this EQA programme are subcontracted.